EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment

The United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent ...
Seeking Alpha

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and ...
Nasdaq

Milestone Pharmaceuticals Inc. Announces Investor Event for Commercial Launch Plan of Etripamil Nasal Spray CARDAMYST™

Milestone Pharmaceuticals announced a Commercial Launch Plan investor event, indicating proactive engagement with investors and transparency about its upcoming strategies. The event will detail the ...
Seeking Alpha

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

LONDON, Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent ...
The Manila Times

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid ...

REZENOPY™ received approval from the U.S. Food and Drug Administration (the "FDA”) on April 19, 2024. The newly issued patent is eligible for listing in the FDA’s Orange Book and, if listed, may ...